Transmission of lymphatic filariasis is mediated through microfilariae (L1 stage of the parasite) which is encased in an eggshell called sheath. The sheath protein Shp-1 stabilizes the structure due to the unique repeat region with Met-Pro-Pro-Gln-Gly sequences. Microfilarial proteins could be used as transmission blocking vaccines. Since the repeat region of Shp-1 was predicted to carry putative B epitopes, this region was used to analyze its reactivity with clinical samples towards construction of peptide vaccine. In silico analysis of Shp-1 showed the presence of B epitopes in the region 49-107. The polypeptide epitopic region Shp-1 49-107 was cloned and expressed in Escherichia coli. Antibody reactivity of the Shp-1 49-107 construct was evaluated in filarial endemic population by ELISA. Putatively immune endemic normals (EN) showed significantly high reactivity (P < 0.05) when compared to all the other categories. Antibody reactivity of Shp-1 repeat region was similar to that of whole protein proving that this region carries B epitopes responsible for its humoral response in humans. Thus this can be employed for inducing anti-microfilarial immunity in the infected population that may lead to reduction in transmission intensity and also it could be used along with other epitopes from different stages of the parasite in order to manage the disease effectively.
Introduction
Filarial nematodes Brugia malayi and Wuchereria bancrofti are responsible for majority of filarial infections globally (WHO, 2013) . Control of the disease requires effective vaccine and drug development approaches. Filarial disease has varying degree of clinical spectrum in human such as asymptomatic with or without microfilariae in their circulation and symptomatic chronic cases. One possible approach in preventing microfilaeremia in endemic population is interrupting transmission by targeting microfilaria (mf) specific antigens.
With the complex developmental cycle, parasites release first stage microfilarial larvae which are thought to be crucial for long term survival of parasites in host owing to immunosuppression and the resulting pathogenicity. Mf sheath is formed by cross linking through disulfide and glutamyl-lysine bonds between sheath proteins and is an essential feature during parasite development and they have been shown to contain tandem repeats (Selkirk et al., 1991) . The major protein expressed in mf sheath, Shp-1 is considered to be immunogenic, and is involved in mf motility (Aboobaker and Blaxter, 2003) . Since microfilarial (Wadee et al., 1987) proteins and adult worm burden in occult infection (Steel et al., 2001) tend to suppress immune response, it would be important to develop vaccine derived from mf stage antigens devoid of immunosuppressive epitopes.
Shp-1 carries a repeat region that has multiple glutamine/prolines and is responsible for its extreme stability and resistance. Repeat regions have been reported in other parasitic diseases like malaria and have been successfully used as peptide vaccines as they usually comprise immunogenic epitopes (Ballou et al., 1985; Mahajan et al., 2010) . Since the repeat region of shp-1 was found to be unique and showed presence of epitopes, the antibody reactivity of Shp-1 repeat region was analyzed in clinical sera of filarial population in the present study towards development of epitope vaccine targeting microfilariae. *Corresponding author: pk.kaliraj@gmail.com
Materials and Methods

Epitope prediction
Protein sequence of BmShp-1 was analyzed for B epitope prediction in silico using Bepipred tool in the IEDB site (Peters et al., 2005) . Predicted region (49-107) consisted of 59 amino acids (MGPQIMQPQGMLPQGMQPQGMQPQGMQPQG-MQPQGMPPQGMRPQGMQPQGMQPQYIEPQ) that was shown to carry B epitopes.
Cloning and expression of Shp-1 49-107
The corresponding gene, Shp-1 145-321 was amplified from the BmShp-1 clone (GenBank Acc. No. EU877233) and cloned in prokaryotic pRSET-B vector (Invitrogen, CA, USA) using primers flanking BamHI and EcoRI restriction sites: FP 5'-CGCGGATCCGATGGGACCGCAGATTATGCAAC-3' and RP 5'-CGGAATTCTCATTGTGG TTCGATGTA-3'. Gene sequence and reading frame was confirmed by sequencing using universal T7 primers. Recombinant Shp-1 49-107 was expressed in E. coli GJ1158 by induction with NaCl at 0.6 OD 600 for 2 hrs and purified by electro elution from preparative Tricine SDS-PAGE. Recombinant BmShp-1 was purified as described previously by Jawaharlal et al., 2014 .
Study population
Blood samples were collected from different endemic areas in Tamil Nadu with prior consent from all patients. Procedures were followed in accordance with the guidelines issued by Department of Public Health, Government of Tamil Nadu, India. The Institutional Review Board at the Centre for Biotechnology, Anna University, India approved the protocols. Filarial population was classified as Endemic Normals (EN) (n=30), who were devoid of microfilaria and asymptomatic, Microfilaeremics (MF) (n=30), who showed microfilariae in circulation with no symptoms and whose sera was positive in Og4C3 kit or Chronic Pathology (CP) (n=30) patients who showed visible symptoms of filariasis with lymphedema. Non Endemic Normal, NEN (n= 30) samples were collected from areas free of filarial infection were selected.
Clinical sera reactivity
Indirect ELISA was carried out to check the reactivity of rBmShp-1 and Shp-1 49-107 in clinical samples. BmShp-1 was used as control to compare the reactivity. ELISA plates were coated with 100 ng of rBmShp-1 or Shp-1 49-107 and incubated overnight at 37 o C. After blocking with 5% non-fat skimmed milk powder, wells were incubated with clinical sera from all population (1:100) for 2 hrs at 37 o C. After washing three times with PBS containing 0.05% Tween-20, plates were incubated with goat anti-human IgG conjugated to alkaline phosphatase (Bangalore Genei, India) for 1 hr at 37 o C. After washing, plates were developed using p-nitrophenyl phosphate substrate substrate and absorbance was read at 405 nm. Reactivity was compared with NEN control sera and cut off value was calculated by taking mean absorbance of NEN sera plus 3 SD to analyze the positive antibody reactivity.
Statistical analysis
Statistical analysis was done with the use of Graphpad Prism software, version 5.0. Mann-Whitney test was used to compare two groups. For multiple comparisons, the nonparametric Kruskal-Wallis and Bonferroni's post tests were used. Probability P value ≤ 0.05 was considered statistically significant.
Results
To compare the immunoreactivity of Shp-1 49-107 with Shp-1, the former was amplified from BmShp-1 gene and subcloned. The clone was confirmed by PCR with gene specific primers (Fig. 1) . The sequencing results showed the presence of 177 bp gene coding for 59 aminoacids and expression of histidine tagged recombinant protein corresponded to ~11 kDa. Purified Shp-1 49-107 protein was analyzed on Tricine SDS-PAGE and confirmed by Western blot ( Fig. 2A and B) . Shp-1 49-107 repeat region was recognized in all clinical population (Fig. 3) and the absorbance was comparable to that of the whole protein Shp-1 (P > 0.05) which indicates that this region is responsible for the antibody reactivity in human samples. Both proteins (Shp-1 and Shp-149-107 ) showed highest reactivity in endemic normal (EN) subjects (Mean OD=0.86 ± 0.37 and 0.85 ± 0.27) and were significant when compared to non endemic normal (NEN) controls (Mean OD=0.12 ± 0.02 and 0.13 ± 0.03) (P < 0.0001). Significant reactivity (P < 0.0001) was seen in microfilaeremic (MF) individuals (Mean OD=0.58 ± 0.11 and 0.58 ± 0.15) and chronic patients (CP) (Mean OD=0.59 ± 0.16 and 0.63 ± 0.22) in comparison to NEN controls and both the proteins were recognized by MF and CP. Significant difference was observed between EN and MF or CP (P < 0.0001).
Discussion
Lymphatic filariasis is a dreadful disease that has broad clinical spectrum. The microfilarial stage of parasite expresses proteins needed to invade the host immune system and for disease progression that leads to increased disease transmission. In order to prevent transmission by effective methods, it is pertinent to develop vaccines targeting mf stage antigens. Since Shp-1 is the key antigen that forms the protective sheath of mf, it could be an effective transmission blocking vaccine. Antibodies against sheath proteins were reported to be effective in clearing microfilariae (McGreevy et al., 1980; Ravindran et al., 2000) . Also microfilarial expressed proteins have been shown to elicit partial protection in animal models (Wang et al., 1997; Wang et al., 1999; Dabir et al., 2008) .
Shp-1 contains a highly repetitive region that is significant for parasite survival as it gives stability and makes the sheath highly resistant to any kind of chemical or enzymatic destruction (Christ et al., 1992) . The region represents a tandem repeat and it has been reported that proteins with repeats are immunogenic and effective in clearance mechanisms (Horii et al., 2010) . In this study, the repeat region of sheath protein Shp-1 was cloned, expressed and its reactivity in filarial clinical population was evaluated. The region 49-107 encompassing tandem repeat recognized antibodies in filarial population, confirming the presence of antibodies in putatively immune individuals against this region. The reactivity of Shp-1 in all clinical population was comparable to that of the Shp-1. It is interesting to note that this region has 100% homology with the repeat region in Wuchereria bancrofti. Hence, Shp-1 49-107 carries the potential B epitopes which can be exploited in filarial epitope vaccine design. Although sequence 49-107 is comprised of only B cell epitopes, it can be used in vaccine design since protection in filariasis is Th2 based and involves antibody dependent parasite killing mechanism (ADCC) (Chandrashekar et al. 1985; Abraham et al. 1989; Chandrashekar et al. 1990) . Moreover, we have demonstrated in our previous study > 70 % protection in a B epitope based vaccine construct (Madhumathi et al. 2010) . Development of protective immunity against different stages of the parasite using effective B or T epitope would provide successful parasite clearance mechanism (Singh et al. 2012) .
